Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.32 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139400 | 0.81 | KMT2A (0.42) | ALDH1A1HSP90AA1GAAKMT2ACYP1A2 | |
| SCHEMBL20139416 | 0.78 | ALDH1A1 (0.39) | ALDH1A1HSP90AA1GAAKMT2ACYP1A2 | |
| SCHEMBL20139451 | 0.78 | KMT2A (0.42) | ALDH1A1HSP90AA1GAAKMT2ACYP1A2 | |
| SCHEMBL20140072 | 0.78 | KMT2A (0.40) | ALDH1A1HSP90AA1GAAKMT2A | |
| SCHEMBL20139452 | 0.72 | ALDH1A1 (0.40) | ALDH1A1HSP90AA1GAAKMT2ACYP1A2 | |
| SCHEMBL20140108 | 0.72 | HTR2A (0.41) | CARM1 | |
| SCHEMBL20139699 | 0.69 | HPGD (0.44) | ALDH1A1HSP90AA1GAAKMT2AHTT | |
| SCHEMBL30616847 | 0.67 | MAPT (0.49) | ALDH1A1GAA | |
| SCHEMBL3159375 | 0.67 | MAPT (0.49) | ALDH1A1GAA | |
| SCHEMBL20139378 | 0.66 | CCR5 (0.36) | CARM1HSD17B3PNMTASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | ALDH1A1 2392/4885HSP90AA1 1912/4885GAA 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.